{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:34:35Z","timestamp":1780634075275,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11864-025-01318-4","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:11:28Z","timestamp":1744359088000},"page":"360-366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral Budesonide in Oncology: A Novel Approach to Managing Gastrointestinal Immune-Related Adverse Events"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-5419","authenticated-orcid":false,"given":"Piotr T.","family":"Wysocki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-3151","authenticated-orcid":false,"given":"Jaros\u0142aw","family":"Regu\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"1","key":"1318_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","volume":"132","author":"B Jayathilaka","year":"2025","unstructured":"Jayathilaka B, Mian F, Franchini F, et al. Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Br J Cancer. 2025;132(1):51\u20137. https:\/\/doi.org\/10.1038\/s41416-024-02887-1.","journal-title":"Br J Cancer"},{"issue":"11","key":"1318_CR2","doi-asserted-by":"publisher","first-page":"e009742","DOI":"10.1136\/jitc-2024-009742","volume":"12","author":"M Shatila","year":"2024","unstructured":"Shatila M, Zhang HC, Shirwaikar Thomas A, et al. Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events. J Immunother Cancer. 2024;12(11):e009742. https:\/\/doi.org\/10.1136\/jitc-2024-009742.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1318_CR3","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001.","journal-title":"Ann Oncol"},{"issue":"1","key":"1318_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.clcc.2023.12.003","volume":"23","author":"K Mok","year":"2024","unstructured":"Mok K, Wu C, Chan S, et al. Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors. Clin Colorectal Cancer. 2024;23(1):4\u201313. https:\/\/doi.org\/10.1016\/j.clcc.2023.12.003.","journal-title":"Clin Colorectal Cancer"},{"issue":"36","key":"1318_CR5","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/jco.21.01440.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1318_CR6","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.Ccr-22-3181","volume":"29","author":"RS Goodman","year":"2023","unstructured":"Goodman RS, Johnson DB, Balko JM. Corticosteroids and Cancer Immunotherapy. Clin Cancer Res. 2023;29(14):2580\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-3181.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1318_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s10620-015-3897-0","volume":"61","author":"GR Lichtenstein","year":"2016","unstructured":"Lichtenstein GR. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. Dig Dis Sci. 2016;61(2):358\u201370. https:\/\/doi.org\/10.1007\/s10620-015-3897-0.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"1318_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/2040622310379293","volume":"1","author":"S O'Donnell","year":"2010","unstructured":"O\u2019Donnell S, O\u2019Morain CA. Therapeutic benefits of budesonide in gastroenterology. Ther Adv Chronic Dis. 2010;1(4):177\u201386. https:\/\/doi.org\/10.1177\/2040622310379293.","journal-title":"Ther Adv Chronic Dis"},{"issue":"9","key":"1318_CR9","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1111\/jgh.14151","volume":"33","author":"S Miehlke","year":"2018","unstructured":"Miehlke S, Acosta MB-D, Bouma G, et al. Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician. J Gastroenterol Hepatol. 2018;33(9):1574\u201381. https:\/\/doi.org\/10.1111\/jgh.14151.","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"1318_CR10","doi-asserted-by":"publisher","first-page":"007698","DOI":"10.1002\/14651858.CD007698.pub3","volume":"2015","author":"ME Sherlock","year":"2015","unstructured":"Sherlock ME, MacDonald JK, Griffiths AM, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;2015(10):007698. https:\/\/doi.org\/10.1002\/14651858.CD007698.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1318_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cgh.2021.04.022","volume":"20","author":"I Hirano","year":"2022","unstructured":"Hirano I, Collins MH, Katzka DA, et al. Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial. Clin Gastroenterol Hepatol. 2022;20(3):525-34.e10. https:\/\/doi.org\/10.1016\/j.cgh.2021.04.022.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1318_CR12","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/gut.40.6.775","volume":"40","author":"JK Marshall","year":"1997","unstructured":"Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40(6):775\u201381. https:\/\/doi.org\/10.1136\/gut.40.6.775.","journal-title":"Gut"},{"issue":"13","key":"1318_CR13","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJM199409293311304","volume":"331","author":"P Rutgeerts","year":"1994","unstructured":"Rutgeerts P, Lofberg R, Malchow H, et al. A Comparison of Budesonide with Prednisolone for Active Crohn\u2019s Disease. New England J Med. 1994;331(13):842\u20135. https:\/\/doi.org\/10.1056\/NEJM199409293311304.","journal-title":"New England J Med"},{"issue":"2","key":"1318_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/gut.41.2.209","volume":"41","author":"M Campieri","year":"1997","unstructured":"Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn\u2019s disease. Gut. 1997;41(2):209\u201314. https:\/\/doi.org\/10.1136\/gut.41.2.209.","journal-title":"Gut"},{"issue":"10","key":"1318_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cgh.2011.06.005","volume":"9","author":"MJ Stewart","year":"2011","unstructured":"Stewart MJ, Seow CH, Storr MA. Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2011;9(10):881\u201390. https:\/\/doi.org\/10.1016\/j.cgh.2011.06.005.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"1318_CR16","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. The Lancet Haematology. 2020;7(2):e157\u201367. https:\/\/doi.org\/10.1016\/S2352-3026(19)30256-X.","journal-title":"The Lancet Haematology"},{"key":"1318_CR17","doi-asserted-by":"publisher","unstructured":"Rezaie A, Kuenzig ME, Benchimol EI, et al. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2015;2015(6). https:\/\/doi.org\/10.1002\/14651858.CD000296.pub4.","DOI":"10.1002\/14651858.CD000296.pub4"},{"issue":"2","key":"1318_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bcp.13456","volume":"84","author":"S Bonovas","year":"2018","unstructured":"Bonovas S, Nikolopoulos GK, Lytras T, et al. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. Br J Clin Pharmacol. 2018;84(2):239\u201351. https:\/\/doi.org\/10.1111\/bcp.13456.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1318_CR19","doi-asserted-by":"publisher","first-page":"CD002913","DOI":"10.1002\/14651858.CD002913.pub3","volume":"2014","author":"ME Kuenzig","year":"2014","unstructured":"Kuenzig ME, Rezaie A, Seow CH, et al. Budesonide for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2014;2014(8):CD002913. https:\/\/doi.org\/10.1002\/14651858.CD002913.pub3.","journal-title":"Cochrane Database Syst Rev."},{"issue":"17","key":"1318_CR20","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1200\/jco.22.02914","volume":"41","author":"DM Faleck","year":"2023","unstructured":"Faleck DM, Dougan M, Tello M, et al. Accelerating the Evolution of Immune-Related Enterocolitis Management. J Clin Oncol. 2023;41(17):3110\u20135. https:\/\/doi.org\/10.1200\/jco.22.02914.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1318_CR21","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1158\/1078-0432.Ccr-09-1024","volume":"15","author":"J Weber","year":"2009","unstructured":"Weber J, Thompson JA, Hamid O, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma. Clin Cancer Res. 2009;15(17):5591\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-1024.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1318_CR22","doi-asserted-by":"publisher","first-page":"e000457","DOI":"10.1136\/esmoopen-2018-000457","volume":"4","author":"G Fuc\u00e0","year":"2019","unstructured":"Fuc\u00e0 G, Galli G, Poggi M, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open. 2019;4(1):e000457. https:\/\/doi.org\/10.1136\/esmoopen-2018-000457.","journal-title":"ESMO Open"},{"issue":"1","key":"1318_CR23","doi-asserted-by":"publisher","first-page":"1824645","DOI":"10.1080\/2162402x.2020.1824645","volume":"9","author":"A Drakaki","year":"2020","unstructured":"Drakaki A, Dhillon PK, Wakelee H, et al. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. Oncoimmunology. 2020;9(1):1824645. https:\/\/doi.org\/10.1080\/2162402x.2020.1824645.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1318_CR24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s40425-019-0756-0","volume":"7","author":"MS Hughes","year":"2019","unstructured":"Hughes MS, Molina GE, Chen ST, et al. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):292. https:\/\/doi.org\/10.1186\/s40425-019-0756-0.","journal-title":"J Immunother Cancer"},{"issue":"10S","key":"1318_CR25","doi-asserted-by":"publisher","first-page":"S2002","DOI":"10.14309\/01.ajg.0001041028.42769.0d","volume":"119","author":"Z Kovach","year":"2024","unstructured":"Kovach Z, Shepherd K, Cohen EM, et al. S2915 Back to the Basics: Use Of Budesonide as the Treatment for Immune Checkpoint Inhibitor Induced Microscopic Colitis Non-Responsive to Prednisone, Infliximab, and Vedolizumab. Am J Gastroenterol. 2024;119(10S):S2002. https:\/\/doi.org\/10.14309\/01.ajg.0001041028.42769.0d.","journal-title":"Am J Gastroenterol."},{"issue":"2","key":"1318_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/ibd\/izy240","volume":"25","author":"K Choi","year":"2019","unstructured":"Choi K, Abu-Sbeih H, Samdani R, et al. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity? Inflamm Bowel Dis. 2019;25(2):385\u201393. https:\/\/doi.org\/10.1093\/ibd\/izy240.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"1318_CR27","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3390\/cancers16101919","volume":"16","author":"AP Machado","year":"2024","unstructured":"Machado AP, Shaikh AS, Saji A, et al. Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor-Related Colitis in Patients with Cancer. Cancers (Basel). 2024;16(10):1919. https:\/\/doi.org\/10.3390\/cancers16101919.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1318_CR28","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/ajg.2017.71","volume":"112","author":"SS Mukewar","year":"2017","unstructured":"Mukewar SS, Sharma A, Rubio-Tapia A, et al. Open-Capsule Budesonide for Refractory Celiac Disease. Am J Gastroenterol. 2017;112(6):959\u201367. https:\/\/doi.org\/10.1038\/ajg.2017.71.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"1318_CR29","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1007\/s10620-024-08436-3","volume":"69","author":"D Saitta","year":"2024","unstructured":"Saitta D, Henneken LM, Apputhurai P, et al. Budesonide Induces Favourable Histologic and Symptomatic Recovery in Patients with Non-responsive and Refractory Coeliac Disease When Given in an Open Capsule Format. Dig Dis Sci. 2024;69(7):2548\u201357. https:\/\/doi.org\/10.1007\/s10620-024-08436-3.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"1318_CR30","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.cgh.2017.12.044","volume":"16","author":"A Sharma","year":"2018","unstructured":"Sharma A, Choung RS, Wang XJ, et al. Features of Adult Autoimmune Enteropathy Compared With Refractory Celiac Disease. Clin Gastroenterol Hepatol. 2018;16(6):877-83.e1. https:\/\/doi.org\/10.1016\/j.cgh.2017.12.044.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"1318_CR31","doi-asserted-by":"publisher","first-page":"e009051","DOI":"10.1136\/jitc-2024-009051","volume":"12","author":"PT Magahis","year":"2024","unstructured":"Magahis PT, Corso T, Livingstone P, et al. Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors. J Immunother Cancer. 2024;12(7):e009051. https:\/\/doi.org\/10.1136\/jitc-2024-009051.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1318_CR32","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1080\/00365521.2019.1594356","volume":"54","author":"T Tang","year":"2019","unstructured":"Tang T, Abu-Sbeih H, Luo W, et al. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol. 2019;54(5):538\u201345. https:\/\/doi.org\/10.1080\/00365521.2019.1594356.","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"1318_CR33","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","volume":"139","author":"MP Manns","year":"2010","unstructured":"Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139(4):1198\u2013206. https:\/\/doi.org\/10.1053\/j.gastro.2010.06.046.","journal-title":"Gastroenterology"},{"issue":"2","key":"1318_CR34","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","volume":"72","author":"CL Mack","year":"2020","unstructured":"Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671\u2013722. https:\/\/doi.org\/10.1002\/hep.31065.","journal-title":"Hepatology"},{"issue":"4","key":"1318_CR35","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/hep.0000000000000018","volume":"77","author":"\u00c1 D\u00edaz-Gonz\u00e1lez","year":"2023","unstructured":"D\u00edaz-Gonz\u00e1lez \u00c1, Hern\u00e1ndez-Guerra M, P\u00e9rez-Medrano I, et al. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration. Hepatology. 2023;77(4):1095\u2013105. https:\/\/doi.org\/10.1097\/hep.0000000000000018.","journal-title":"Hepatology"},{"issue":"4","key":"1318_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40472-024-00441-9","volume":"11","author":"D Liu","year":"2024","unstructured":"Liu D, Bonwick WMW, Sumithran P, et al. Budesonide in Liver Immunology: A Therapeutic Opportunity in Liver Transplantation. Curr Trans Rep. 2024;11(4):197\u2013206. https:\/\/doi.org\/10.1007\/s40472-024-00441-9.","journal-title":"Curr Trans Rep"},{"issue":"31","key":"1318_CR37","doi-asserted-by":"publisher","first-page":"e29473","DOI":"10.1097\/md.0000000000029473","volume":"101","author":"G Eleftheriotis","year":"2022","unstructured":"Eleftheriotis G, Skopelitis E. Immune-checkpoint inhibitor-associated grade 3 hepatotoxicity managed with enteric-coated budesonide monotherapy: A case report. Medicine (Baltimore). 2022;101(31):e29473. https:\/\/doi.org\/10.1097\/md.0000000000029473.","journal-title":"Medicine (Baltimore)"},{"issue":"10S","key":"1318_CR38","doi-asserted-by":"publisher","first-page":"S2481","DOI":"10.14309\/01.ajg.0000965188.32051.39","volume":"118","author":"M Chopra","year":"2023","unstructured":"Chopra M, Zhang HC. S3887 Recognition of Delayed-Onset Immune Checkpoint Inhibitor-Mediated Hepatotoxicity Treated With Budesonide: A Case Study Factoring in Pharmacokinetics of Immunotherapies. Am J Gastroenterol. 2023;118(10S):S2481\u20132. https:\/\/doi.org\/10.14309\/01.ajg.0000965188.32051.39.","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"1318_CR39","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","volume":"66","author":"M Ziemer","year":"2017","unstructured":"Ziemer M, Koukoulioti E, Beyer S, et al. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol. 2017;66(3):657\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2016.11.015.","journal-title":"J Hepatol"},{"key":"1318_CR40","doi-asserted-by":"publisher","unstructured":"Kankaria RA, Johnson DB. Steroid-refractory immune mediated hepatitis managed with budesonide in patients with metastatic melanoma: proof of concept and literature review. The Oncologist. 2025;30(1). https:\/\/doi.org\/10.1093\/oncolo\/oyae361.","DOI":"10.1093\/oncolo\/oyae361"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01318-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01318-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01318-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T05:14:38Z","timestamp":1746508478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01318-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01318-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"31 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}